Derek Archila
Stock Analyst at Wells Fargo
(4.22)
# 412
Out of 5,072 analysts
202
Total ratings
54.48%
Success rate
12.83%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANNX Annexon | Maintains: Overweight | $14 → $27 | $4.44 | +508.11% | 4 | Nov 19, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $20 → $19 | $11.62 | +63.51% | 1 | Nov 14, 2025 | |
| SEPN Septerna | Upgrades: Overweight | $18 → $28 | $27.97 | +0.11% | 5 | Nov 14, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $76 → $84 | $70.63 | +18.93% | 1 | Nov 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $395 → $479 | $429.80 | +11.45% | 1 | Nov 11, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Overweight | $11 → $14 | $10.46 | +33.84% | 5 | Nov 7, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Equal-Weight | $10 → $13 | $16.02 | -18.85% | 6 | Nov 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $16 → $15 | $12.12 | +23.76% | 8 | Nov 6, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $123 → $106 | $49.77 | +112.98% | 2 | Nov 5, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $53 → $69 | $66.04 | +4.48% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $41.49 | +95.23% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $31 | $7.39 | +319.49% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $89 → $97 | $105.55 | -8.10% | 10 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $21 | $17.00 | +23.53% | 6 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $43.13 | -30.44% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.28 | -20.38% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $32 | $21.00 | +52.38% | 13 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $2.48 | +303.23% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.77 | +30.31% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $26.44 | +43.72% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $0.86 | +248.84% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.20 | -9.09% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $289 → $295 | $206.65 | +42.75% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $1.44 | +247.22% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $26 | $31.41 | -17.22% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $741 → $756 | $917.93 | -17.64% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $7.33 | +131.92% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $108.75 | +18.62% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $2.03 | +638.92% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $26.18 | -46.52% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $23.95 | +87.89% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.69 | +442.01% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.42 | +307.24% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $31.12 | +520.18% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $70.88 | -42.16% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $15.72 | +917.81% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $12.96 | +362.96% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $5.00 | +480.00% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.09 | +4,487.16% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $27.69 | +84.18% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $12.92 | +581.11% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $23.17 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $24.99 | - | 2 | Aug 3, 2017 |
Annexon
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $4.44
Upside: +508.11%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $11.62
Upside: +63.51%
Septerna
Nov 14, 2025
Upgrades: Overweight
Price Target: $18 → $28
Current: $27.97
Upside: +0.11%
BridgeBio Pharma
Nov 11, 2025
Maintains: Overweight
Price Target: $76 → $84
Current: $70.63
Upside: +18.93%
Alnylam Pharmaceuticals
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $395 → $479
Current: $429.80
Upside: +11.45%
Ventyx Biosciences
Nov 7, 2025
Maintains: Overweight
Price Target: $11 → $14
Current: $10.46
Upside: +33.84%
Monte Rosa Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $10 → $13
Current: $16.02
Upside: -18.85%
Arvinas
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $12.12
Upside: +23.76%
Soleno Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $123 → $106
Current: $49.77
Upside: +112.98%
Kymera Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $53 → $69
Current: $66.04
Upside: +4.48%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $41.49
Upside: +95.23%
Oct 30, 2025
Maintains: Overweight
Price Target: $27 → $31
Current: $7.39
Upside: +319.49%
Oct 29, 2025
Maintains: Overweight
Price Target: $89 → $97
Current: $105.55
Upside: -8.10%
Oct 23, 2025
Maintains: Overweight
Price Target: $22 → $21
Current: $17.00
Upside: +23.53%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $43.13
Upside: -30.44%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.28
Upside: -20.38%
Oct 15, 2025
Upgrades: Overweight
Price Target: $29 → $32
Current: $21.00
Upside: +52.38%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.48
Upside: +303.23%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.77
Upside: +30.31%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $26.44
Upside: +43.72%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.86
Upside: +248.84%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.20
Upside: -9.09%
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $206.65
Upside: +42.75%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.44
Upside: +247.22%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $31.41
Upside: -17.22%
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $917.93
Upside: -17.64%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $7.33
Upside: +131.92%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $108.75
Upside: +18.62%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $2.03
Upside: +638.92%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $26.18
Upside: -46.52%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $23.95
Upside: +87.89%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.69
Upside: +442.01%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $4.42
Upside: +307.24%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $31.12
Upside: +520.18%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $70.88
Upside: -42.16%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $15.72
Upside: +917.81%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $12.96
Upside: +362.96%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $5.00
Upside: +480.00%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.09
Upside: +4,487.16%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $27.69
Upside: +84.18%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $12.92
Upside: +581.11%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $23.17
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $24.99
Upside: -